ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, today announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
